Advanced searches left 3/3

Metoprolol - Crossref

Summarized by Plex Scholar
Last Updated: 23 April 2022

* If you want to update the article please login/register

A NEW RP-UPLC METHOD FOR SIMULTANEOUS QUANTIFICATION OF IVABRADINE AND METOPROLOL IN COMBINED DOSAGE FORMS

Using Reversed-Phase Ultra-Performance Chromatography, an accurate and yet quick, inexpensive, fast, simple, precise, single method for testing Ivabradine and Metoprolol in bulk and pharmaceutical products was created. At a flow rate of 0. 5 ml/min, a Hibar C18 column was used with a running phase made up of Water: ACN. The correlation between Ivabradine and Metoprolol were found to be 99. 9% and % MSD 2.

Source link: https://doi.org/10.37896/ymer21.04/35


Development of Extended-Release Mini-Tablets Containing Metoprolol Supported by Design of Experiments and Physiologically Based Biopharmaceutics Modeling

As in Biopharmaceutics Classification System class I, pharmaceutical companies face a challenge for pharmaceutical firms, mainly because the drug has high solubility. This paper was designed to produce extended-release mini-tablets containing metoprolol succinate, while simultaneously integrating experimental and physiologically based biopharmaceutics modeling to determine absorption and performing virtual bioequivalence studies in both fasted and fed states. When doing VBE experiments in both fasted and fed states, an optimized formulation containing a mixture of immediate and extended-release mini-tablets proved to be bioequivalent to the reference drug product containing MS.

Source link: https://doi.org/10.3390/pharmaceutics14050892


Metoprolol Improves Myocardial Remodeling and Cardiac Function in Patients with Permanent Pacemaker Implantation

After permanent pacemaker implantation, the aim of this study was to investigate the clinical utility of metoprolol in patients. According to whether metoprolol is used in a medical clinic and 45 patients in each group, ninety patients with permanent dual-chamber pacemaker implantation in our hospital are chosen and divided into a metoprolol group and a control group one week after the operation and 45 patients in each group. The E/A of the metoprolol group is higher than that of the control group p 0. 05, and LVED and LAD are lower than those of the control group P 0. 05 in the measurements obtained immediately postoperatively. At 12 months after pacemaker implantation, the metoprolol group's NT-proBNP is lower than that of the control group p 0. 05. QTd, Pd, and Tp-Te in the metoprolol group are not significantly different from the control group and the control group, but the QTd and Pd times in the metoprolol group are slower than those in the control group, which is less than 0. 05 at the 12-month follow-up. The serum IL-6 and TNF- levels in both the metoprolol and control groups are not significantly different one week after the surgery, with a p > 0. 05. The serum IL-6 and TNF- levels in the metoprolol group are lower than those in the control group at 12 months after surgery. p 0. 05 — The use of metoprolol in patients with permanent pacemaker implantation after surgery will reduce the expansionary remodeling of the left atrium and has less effect on the QT-dispersion and Pd times.

Source link: https://doi.org/10.1155/2022/7340992


Predictor of Syncopal Recurrence in Children With Vasovagal Syncope Treated With Metoprolol

Object: To investigate the potential predictors of syncope recurrence in a pediatric population of vaping syncope treated with metoprolol, sees in this case. Study Methods This review was carried out retrospectively among children suffering from VVS with or without syncopal recurrence. From the electronic medical records, data on the detailed medical history and auxiliary examinations were retrieved. According to Cox regression studies, the number of previous syncopal episodes before treatment was a risk factor for syncopal recurrence. In addition, 4 previous syncopal episodes were rated as the best cutoff value, and the Kaplan–Meier curves showed that the syncopal survival rate among patients with >4 episodes was significantly lower than that in patients with fewer than 4 episodes. Conclusion Although focusing on metoprolol therapy, the number of previous syncopal episodes before treatment was instrumental in predicting syncope recurrence.

Source link: https://doi.org/10.3389/fped.2022.870939


Impact of the CYP2D6 Genotype on Metoprolol Tolerance and Adverse Events in Elderly Chinese Patients With Cardiovascular Diseases

The most recent consensus has changed CYP2D6 genotyping among Chinese citizens, while the effect of metoprolol tolerance and adverse events in elderly Chinese patients with cardiovascular disease remains unclear. We prospectively included elderly patients who started metoprolol therapy for cardiovascular indications in this research. IMs had the lowest maintenance dose [50. 0 mg/day, p 0. 001] and lower weight-adjusted maintenance doses after 12 weeks of follow-up, and a higher risk of postural hypotension, bradycardia, asystole, and syncope were also present in IMOs. The overall incidence of adverse events in IMs was 1. 37-fold greater in IMs than in NMs, according to the logistic regression model. IMs have reduced tolerance and a higher risk of metoprolol-related adverse events in elderly Chinese patients with cardiovascular disease than NMs, according to our findings.

Source link: https://doi.org/10.3389/fphar.2022.876392


Differential Role of Calcium/Calmodulin-dependent Protein Kinase II in Desflurane-induced Preconditioning and Cardioprotection by Metoprolol

Pentobarbital-anesthetized New Zealand White rabbits were deviceed for systemic hemodynamic analysis and exposure to 30 minutes of coronary artery occlusion followed by 3 h of reperfusion. In the absence or presence of a 1. 0 minimum algal concentration desflurane, rabbitts were expected to receive vehicle 0. 2, 1. 0, 1. 75, or 2. 5 mg/kg metoprolol for 30 min, or the CaMK II inhibitor KN-93. Western blotting measured protein expression of CaMK II, phospholamban, and phosphophospholamban. The CaMK II inhibitor KN-93 did not impact infarct size, but it did not interfere with desflurane-induced preconditioning. According to metoprolol, 0. 75 and 2. 5 mg/kg had no effect on infarct size, although metoprolol's 1. 75 and 2. 5 mg/kg reduced infarct size to 48 +/- 5%* and 39 +/- 5%, respectively.

Source link: https://doi.org/10.1097/aln.0b013e31817be96c


Metoprolol Reduces Cerebral Tissue Oxygen Tension after Acute Hemodilution in Rats

This paper investigated the effect of beta-blockade on cerebral tissue oxygen delivery in an experimental model of blood loss and fluid resuscitation. Anesthetized rats were first treated with metoprolol or saline before they were subjected to pentastarch hemodilution. By Western blot, hypoxia inducible factor-1alpha protein levels were determined. Despite a noticeable decrease in blood oxygen content, hemodilution raised heart rate, stroke volume, cardiac output, and cerebral blood flow, thereby maintaining PBrO2 after a nearly 50% reduction in blood oxygen content. In beta-blocked hemodiluted rats relative to hemodiluted controls, Cerebral HIF-1alpha protein levels were elevated in comparison to hemodiluted controls. After hemodilution in both groups, systemic catecholamine and erythropoietin levels increased, respectively, whereas angiotensin II levels increased only after beta-blockade and hemodilution. Acute beta-blockade stifled the compensatory cardiac output response to hemodilution, leading to a decrease in cerebral tissue oxygen tension and increased expression of HIF-1alpha.

Source link: https://doi.org/10.1097/aln.0b013e3181b87f0e


Bioanalytical Method Development and Validation of Cilnidipine and Metoprolol Succinate by RP-HPLC: Its Pharmacokinetic Application

Methods: Using the chromatographic technique, a pharmacokinetic study of Cilnidipine and Metoprolol Succinate in rat plasma was carried out. Methods: The chromatographic technique used a reverse phase C18 column, using acetonitrile and pH 4. 0 water in the ratio of 80:20 v/v as the mobile phase, with a flow rate of 1. 2 ml/min as a mobile phase, and UV detection at 231 nm. Results: Plasma, Cilnidipine, and Metoprolol Succinate's retention time was found to be 2. 3, 3. 1, and 5. 5 min, respectively, according to researchers. 100. 12 and 100. 15, respectively, in mean recovery of Cilnidipine and Metoprolol Succinate. Cilnidipine and Metoprolol Succinate's maximum concentration was found to be 460. 01 and 642. 13, respectively, after oral administration, and the halflife was recorded at 2. 0 and 3. 904 hours. After oral administration, the present protocol was successfully applied to the pharmacokinetic study of Cilnidipine and Metoprolol Succinate in rat plasma.

Source link: https://doi.org/10.2174/2210676611666210616142035


Formulation of Metoprolol Bilayer Tablets as an Oral Modified Release Dosage Form

Metoprolol, a Î21 adrenergic blocker used in heart disease prevention, is used in heart disease treatment. Metoprolol tablets were introduced as a new release oral device incorporating the idea of bilayer technology, with the first layer being available as an immediate release and the other being in a sustained release matrix. The layer, which contained microcrystalline cellulose and 2% sodium starch glycolate, had a disintegration time similar to that of a conventional metoprolol tartrate tablet, according to the study.

Source link: https://doi.org/10.31351/vol19iss1pp21-30

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions